New Perspectives on Overactive Bladder: Quality of Life Impact, Medication Persistency, and Treatment CostsByC. Daniel Mullins, PhD,Leslee L. Subak, MDJuly 15th 2005
Persistence With Overactive Bladder Pharmacotherapy in a Medicaid PopulationByFadia T. Shaya, PhD, MPH,Steven Blume, MS,Anna Gu, MA,Teresa Zyczynski, PharmD, MBA, MPH,Zhanna Jumadilova, MD, MBAJuly 15th 2005
The Impact of Urinary Incontinence on Quality of Life of the ElderlyByYu Ko, MS,Swu-Jane Lin, PhD,J. Warren Salmon, PhD,Morgan S. Bron, PharmD, MSJuly 15th 2005
Safety and Tolerability of Tolterodine for the Treatment of Overactive Bladder in AdultsByRichard G. Roberts, MD, JD,Alan D. Garely, MD,Tamara Bavendam, MDJuly 15th 2005
Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost EstimatesByNicole M. Nitz, PhD,Zhanna Jumadilova, MD, MBA,Theodore Darkow, PharmD,Jennifer R. Frytak, PhD,Tamara Bavendam, MDJuly 15th 2005
Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive BladderBySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPHJuly 15th 2005
Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug TreatmentByZhanna Jumadilova, MD, MBA,Teresa Zyczynski, PharmD, MBA, MPH,Barbara Paul, MD,Siva Narayanan, MS, MHSJuly 15th 2005
Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and OxybutyninByEleanor M. Perfetto, PhD,Prasun Subedi, MS,Zhanna Jumadilova, MD, MBAJuly 15th 2005
